4MT2001
Bipolar Disorder
Pre-clinicalActive
Key Facts
About 4M Therapeutics
4M Therapeutics is a private, preclinical-stage biotech focused on central nervous system (CNS) disorders. Its core strategy involves using a human brain cell platform to discover and develop small molecules targeting neuroplasticity, neurogenesis, and neuroinflammation. The lead program, 4MT2001, is a GSK3β inhibitor positioned as a safer alternative to lithium for bipolar disorder, with a broader pipeline targeting agitation in Alzheimer's and neurodegeneration. The company is led by an experienced team with strong academic and industry backgrounds.
View full company profileTherapeutic Areas
Other Bipolar Disorder Drugs
| Drug | Company | Phase |
|---|---|---|
| AL001 | Alzamend Neuro | Phase II |
| Undisclosed Programs | johnson-and-johnson-innovative-medicine | Pipeline |
| ALM008 | Almatica Pharma | Phase 2 |
| Bipolar Disorder Studies | Pacific Clinical Research Medical Group | Phase 2/3 |
| RAP-219 | Rapport Therapeutics | Discovery |